PMID- 20540643
OWN - NLM
STAT- MEDLINE
DCOM- 20101124
LR  - 20231213
IS  - 1525-6049 (Electronic)
IS  - 0886-022X (Linking)
VI  - 32
IP  - 6
DP  - 2010 Jul
TI  - Silymarin and milk thistle extract may prevent the progression of diabetic 
      nephropathy in streptozotocin-induced diabetic rats.
PG  - 733-9
LID - 10.3109/0886022X.2010.486488 [doi]
AB  - OBJECTIVES: To investigate the effect of silymarin and milk thistle extract on 
      the progression of diabetic nephropathy (DN) in rats. METHODS: Diabetes was 
      induced with a single intraperitoneal (IP) injection of streptozotocin (STZ) (60 
      mg/kg). Silymarin (100 mg/kg/d) or the extract (1.2 g/kg/d) was gavaged for 4 
      weeks. Blood glucose (BS), serum urea (S(u)), serum creatinine (S(cr)), and 24-h 
      urine protein (Up) were measured and glomerular filtration rate (GFR) was 
      calculated. Concentration of thiobarbituric acid reactive species (TBARS) and 
      activities of glutathione peroxidase (GPx), superoxide dismutase (SOD), and 
      catalase (CAT) were evaluated in the renal tissue. RESULTS: Data were expressed 
      as mean +/- SEM. Silymarin or the extract had no significant effect on BS, S(cr), 
      and GFR. Both milk thistle extract and silymarin, respectively, decreased S(u) 
      (mg/dL) (87.1 +/- 7.78, p < 0.001; 84.5 +/- 7.15, p < 0.001), Up (mg) (5.22 +/- 
      1.56, p = 0.014; 5.67 +/- 0.86, p = 0.034), and tissue TBARS (nmol/mg protein) 
      (0.67 +/- 0.04, p < 0.001; 0.63 +/- 0.07, p < 0.001) in diabetic rats, compared 
      to diabetic control (DC) (S(u): 131.0 +/- 4.55, Up: 8.3 +/- 0.84, TBARS: 0.94 +/- 
      0.06). Both the extract and silymarin could increase the activity of CAT (IU/mg 
      protein) (25.5 +/- 4.0, p = 0.005; 20 +/- 1.8, p = 0.16) and GPx (IU/mg protein) 
      (0.86 +/- 0.05, p = 0.005; 0.74 +/- 0.04, p = 0.10), respectively, in diabetic 
      rats compared to DC (CAT = 14.4 +/- 2.0, GPx = 0.57 +/- 0.02). CONCLUSION: Milk 
      thistle extract, to a lesser extent silymarin, can attenuate DN in rats possibly 
      by increasing kidney CAT and GPx activity and decreasing lipid peroxidation in 
      renal tissue.
FAU - Vessal, Ghazal
AU  - Vessal G
AD  - Department of Clinical Pharmacy, Shiraz Pharmaceutical Research Center, Faculty 
      of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Islamic Republic of 
      Iran. gvessal@yahoo.com
FAU - Akmali, Masoumeh
AU  - Akmali M
FAU - Najafi, Parisa
AU  - Najafi P
FAU - Moein, Mahmood Reza
AU  - Moein MR
FAU - Sagheb, Mohammad Mahdi
AU  - Sagheb MM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Ren Fail
JT  - Renal failure
JID - 8701128
RN  - 0 (Plant Extracts)
RN  - 0 (Protective Agents)
RN  - 0 (Silymarin)
RN  - 5W494URQ81 (Streptozocin)
SB  - IM
MH  - Animals
MH  - Diabetes Mellitus, Experimental/chemically induced
MH  - Diabetic Nephropathies/*prevention & control
MH  - Disease Progression
MH  - Male
MH  - *Silybum marianum
MH  - *Phytotherapy
MH  - Plant Extracts/*therapeutic use
MH  - Protective Agents/*therapeutic use
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Silymarin/*therapeutic use
MH  - Streptozocin
EDAT- 2010/06/15 06:00
MHDA- 2010/12/14 06:00
CRDT- 2010/06/15 06:00
PHST- 2010/06/15 06:00 [entrez]
PHST- 2010/06/15 06:00 [pubmed]
PHST- 2010/12/14 06:00 [medline]
AID - 10.3109/0886022X.2010.486488 [doi]
PST - ppublish
SO  - Ren Fail. 2010 Jul;32(6):733-9. doi: 10.3109/0886022X.2010.486488.